{"id":724999,"date":"2023-01-23T09:07:10","date_gmt":"2023-01-23T14:07:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\/"},"modified":"2023-01-23T09:07:10","modified_gmt":"2023-01-23T14:07:10","slug":"neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\/","title":{"rendered":"NeuroMetrix\u00ae Announces Launch of DPNCheck\u00ae 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy"},"content":{"rendered":"<h2>\nPoint-of-care technology helps healthcare providers rapidly identify at-risk patients<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">WOBURN, Mass., Jan.  23, 2023  (GLOBE NEWSWIRE) &#8212; NeuroMetrix, Inc. (Nasdaq: NURO) today announced the commercial availability of DPNCheck 2.0, the Company&#8217;s latest point-of-care device that leverages gold-standard nerve conduction technology to detect peripheral neuropathy. DPNCheck 2.0 provides rapid patient screening with quantitative measurement of peripheral nerve function. It features an easy-to-use touchscreen, onboard step-by-step instructions, improved temperature compensation, real-time nerve response display and other enhancements. Its companion software facilitates clinical documentation of test results. Cloud-based aggregation of population-health data and integration with provider EHR systems is planned for later this year.<\/p>\n<p>Peripheral neuropathy, the systemic degeneration of peripheral nerves, is a common and debilitating condition that may affect up to 30% of the Medicare-aged population. An increasing number of healthcare providers and health plans that support the Medicare population have recently turned their attention to early detection and management of this condition to help reduce their patients\u2019 risk of foot ulcers, falls, pain and other complications. By incorporating screening for peripheral neuropathy using nerve conduction technology, it is possible to uncover elevated risk for these complications earlier and more accurately than traditional clinical approaches such as the monofilament and tuning fork tests.<\/p>\n<p>\u201cFor more than a decade, our first-generation DPNCheck device has been used and trusted by thousands of providers to assess over 2-million patients,\u201d said\u00a0Shai N. Gozani, M.D., Ph.D., Chief Executive Officer,\u00a0NeuroMetrix. \u201cWe are excited to launch our newest version to even better address the needs of our clinical partners. We\u2019ve opened the door to more widespread screening with a user-friendly design that makes it faster and easier for care organizations to roll out and train their point-of-care staff and deploy testing.\u201d<\/p>\n<p>DPNCheck 2.0 will be presented at the Medicare Advantage Leadership Innovations National Conference January 24-25, 2023 at the Renaissance Glendale, AZ. Please visit Neurometrix booth #21 to see the device in action and learn more from NeuroMetrix\u2019s value-based care and population health experts. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vmX1v0VapVNnl0uisCxf0ycdsGQ0gNFxDsB_znJASCRpdFDfBU8R__6Ky0Icbig2IRz1-gmIlISCbn_jQXUdEA==\" rel=\"nofollow noopener\" target=\"_blank\">www.DPNCheck.com<\/a>.<\/p>\n<p>\n        <strong>About NeuroMetrix<\/strong>\n      <\/p>\n<p>NeuroMetrix is an innovation-driven company with a mission to improve individual and population health through novel medical devices and technology solutions for neurological disorders and pain syndromes. The Company has three commercial products. DPNCheck<sup>\u00ae<\/sup> is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE<sup>\u00ae<\/sup> is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of focal neuropathies. Quell<sup>\u00ae<\/sup> Fibromyalgia is a wearable neuromodulator that is the first and only FDA-authorized medical device to help reduce the symptoms of fibromyalgia. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6fR6ROZuC-rEXoG0zxIuGpIW7MYnF_Bu4EbtTvAIEc5CPxg5ghbD171iU3QM6mSIyY_Tq_1m913BgbVqehMJfWlWQwyehhgP6DLGoB9WIpw=\" rel=\"nofollow noopener\" target=\"_blank\">www.neurometrix.com<\/a>.<\/p>\n<p>Source: NeuroMetrix, Inc.<\/p>\n<p>Thomas T. Higgins <br \/>SVP and Chief Financial Officer <br \/>781-314-2761 <br \/>neurometrix.ir@neurometrix.com<\/p>\n<p>A photo accompanying this announcement is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GYk0kZFJ8r4QKRPDeQzg67jQde_ugiP4zsABTvHHwHI0EYxty4Ywqr6-mSEfV8OOgG9mhUekj-cvcrIRUFYmrhfhxWEu44XrifkuSneXWSPtiB7EzAXyBbccblOFAna2jogAbJVshbW3V0hwkw0YPbQDC7ZC3tr8dduTHgy0kPS4xyTKbklrMYOMyP_t1XttKBYBJ2sgXrMmneI30Pt59YHNdGylqP4t3imI5CjhTBLqos5TOUiF06eIazLnHGQNb4T2DyZDUromM1h8IBXFyw==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/aee7be42-c171-4ca3-90f7-e46344542209<\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczMzc0MCM1MzY2NjkzIzIwMDgwNDg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/M2JiYTY0YWYtNTZkZi00ODJkLTgxMDQtYjFhNjM1NDQyZGE1LTEwMTk2MjE=\/tiny\/NeuroMetrix-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Point-of-care technology helps healthcare providers rapidly identify at-risk patients WOBURN, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) &#8212; NeuroMetrix, Inc. (Nasdaq: NURO) today announced the commercial availability of DPNCheck 2.0, the Company&#8217;s latest point-of-care device that leverages gold-standard nerve conduction technology to detect peripheral neuropathy. DPNCheck 2.0 provides rapid patient screening with quantitative measurement of peripheral nerve function. It features an easy-to-use touchscreen, onboard step-by-step instructions, improved temperature compensation, real-time nerve response display and other enhancements. Its companion software facilitates clinical documentation of test results. Cloud-based aggregation of population-health data and integration with provider EHR systems is planned for later this year. Peripheral neuropathy, the systemic degeneration of peripheral nerves, is a common and debilitating condition that may affect up to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NeuroMetrix\u00ae Announces Launch of DPNCheck\u00ae 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-724999","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NeuroMetrix\u00ae Announces Launch of DPNCheck\u00ae 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeuroMetrix\u00ae Announces Launch of DPNCheck\u00ae 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Point-of-care technology helps healthcare providers rapidly identify at-risk patients WOBURN, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) &#8212; NeuroMetrix, Inc. (Nasdaq: NURO) today announced the commercial availability of DPNCheck 2.0, the Company&#8217;s latest point-of-care device that leverages gold-standard nerve conduction technology to detect peripheral neuropathy. DPNCheck 2.0 provides rapid patient screening with quantitative measurement of peripheral nerve function. It features an easy-to-use touchscreen, onboard step-by-step instructions, improved temperature compensation, real-time nerve response display and other enhancements. Its companion software facilitates clinical documentation of test results. Cloud-based aggregation of population-health data and integration with provider EHR systems is planned for later this year. Peripheral neuropathy, the systemic degeneration of peripheral nerves, is a common and debilitating condition that may affect up to &hellip; Continue reading &quot;NeuroMetrix\u00ae Announces Launch of DPNCheck\u00ae 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-23T14:07:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczMzc0MCM1MzY2NjkzIzIwMDgwNDg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NeuroMetrix\u00ae Announces Launch of DPNCheck\u00ae 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy\",\"datePublished\":\"2023-01-23T14:07:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\\\/\"},\"wordCount\":479,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczMzc0MCM1MzY2NjkzIzIwMDgwNDg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\\\/\",\"name\":\"NeuroMetrix\u00ae Announces Launch of DPNCheck\u00ae 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczMzc0MCM1MzY2NjkzIzIwMDgwNDg=\",\"datePublished\":\"2023-01-23T14:07:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczMzc0MCM1MzY2NjkzIzIwMDgwNDg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczMzc0MCM1MzY2NjkzIzIwMDgwNDg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeuroMetrix\u00ae Announces Launch of DPNCheck\u00ae 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeuroMetrix\u00ae Announces Launch of DPNCheck\u00ae 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\/","og_locale":"en_US","og_type":"article","og_title":"NeuroMetrix\u00ae Announces Launch of DPNCheck\u00ae 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy - Market Newsdesk","og_description":"Point-of-care technology helps healthcare providers rapidly identify at-risk patients WOBURN, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) &#8212; NeuroMetrix, Inc. (Nasdaq: NURO) today announced the commercial availability of DPNCheck 2.0, the Company&#8217;s latest point-of-care device that leverages gold-standard nerve conduction technology to detect peripheral neuropathy. DPNCheck 2.0 provides rapid patient screening with quantitative measurement of peripheral nerve function. It features an easy-to-use touchscreen, onboard step-by-step instructions, improved temperature compensation, real-time nerve response display and other enhancements. Its companion software facilitates clinical documentation of test results. Cloud-based aggregation of population-health data and integration with provider EHR systems is planned for later this year. Peripheral neuropathy, the systemic degeneration of peripheral nerves, is a common and debilitating condition that may affect up to &hellip; Continue reading \"NeuroMetrix\u00ae Announces Launch of DPNCheck\u00ae 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\/","og_site_name":"Market Newsdesk","article_published_time":"2023-01-23T14:07:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczMzc0MCM1MzY2NjkzIzIwMDgwNDg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NeuroMetrix\u00ae Announces Launch of DPNCheck\u00ae 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy","datePublished":"2023-01-23T14:07:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\/"},"wordCount":479,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczMzc0MCM1MzY2NjkzIzIwMDgwNDg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\/","name":"NeuroMetrix\u00ae Announces Launch of DPNCheck\u00ae 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczMzc0MCM1MzY2NjkzIzIwMDgwNDg=","datePublished":"2023-01-23T14:07:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczMzc0MCM1MzY2NjkzIzIwMDgwNDg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczMzc0MCM1MzY2NjkzIzIwMDgwNDg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurometrix-announces-launch-of-dpncheck-2-0-its-fast-accurate-quantitative-screening-test-for-peripheral-neuropathy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NeuroMetrix\u00ae Announces Launch of DPNCheck\u00ae 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/724999","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=724999"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/724999\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=724999"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=724999"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=724999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}